High-dose therapy (HDT) followed by autologous stem cell support is widely used as intensification treatment in patients with multiple myeloma (MM) responsive to the initial chemotherapy. However, there is growing evidence that only the subset of patients who achieve complete remission (CR) actually benefit from this approach. The aim of this study was to identify pretransplant predictors of CR in responding myeloma patients intensified with HDT. A total of 59 patients with chemosensitive disease received myeloablative therapy. The intensification regimen consisted of MEL-200 (23), MEL-140/TBI 12 Gy (21) or busulfan-based regimens (15). Serum and urine negative immunofixation were required for CR. After HDT, the CR rate increased from 8 to 37%. For the overall series, the median event-free survival (EFS) and overall survival (OS) from the initiation of therapy were 41 and 68 months, respectively. Patients who achieved CR had an EFS (median 47 vs 36 months; P ¼ 0.023) as well as an OS (median not reached vs 60 months; P ¼ 0.006) significantly longer than those attaining a lower degree of response. Finally, the pretransplant features significantly associated to CR were a low M-protein size (serum p10 g/l and urine o0.5 g/24 h) (P ¼ 0.0003) and a proportion of bone marrow plasma cells of p5% (P ¼ 0.02).
Summary:
High-dose therapy (HDT) followed by autologous stem cell support is widely used as intensification treatment in patients with multiple myeloma (MM) responsive to the initial chemotherapy. However, there is growing evidence that only the subset of patients who achieve complete remission (CR) actually benefit from this approach. The aim of this study was to identify pretransplant predictors of CR in responding myeloma patients intensified with HDT. A total of 59 patients with chemosensitive disease received myeloablative therapy. The intensification regimen consisted of MEL-200 (23), MEL-140/TBI 12 Gy (21) or busulfan-based regimens (15) . Serum and urine negative immunofixation were required for CR. After HDT, the CR rate increased from 8 to 37%. For the overall series, the median event-free survival (EFS) and overall survival (OS) from the initiation of therapy were 41 and 68 months, respectively. Patients who achieved CR had an EFS (median 47 vs 36 months; P ¼ 0.023) as well as an OS (median not reached vs 60 months; P ¼ 0.006) significantly longer than those attaining a lower degree of response. Finally, the pretransplant features significantly associated to CR were a low M-protein size (serum p10 g/l and urine o0.5 g/24 h) (P ¼ 0.0003) and a proportion of bone marrow plasma cells of p5% (P ¼ 0.02). Conventional chemotherapy is of limited efficacy in patients with multiple myeloma (MM). 1,2 During the last decade, high-dose therapy (HDT) followed by autologous stem cell support has been increasingly used as intensification treatment for patients with newly diagnosed MM.
Although in most reports a higher complete remission rates after intensive therapy have been achieved, the role of autotransplantation in MM still remains controversial. Thus, there are two randomized studies, 3, 4 one case control 5 and two population-based control studies, 6, 7 showing the superiority of HDT vs standard chemotherapy in terms of event-free survival (EFS) and overall survival (OS). In contrast, there are two randomized 8, 9 studies reporting no survival benefit of HDT compared to chemotherapy. On the other hand, two studies showed that patients with chemosensitive disease to the initial treatment and who met the eligibility criteria for HDT intensification but who were continued on standard chemotherapy, had a survival similar to that of those who were intensified with HDT. 10, 11 Interestingly, there is growing evidence that patients who achieve CR after transplant are only those who seem to gain benefit from the procedure. 12, 13 Therefore, the study of predictor features of complete remission after transplant is important to select those patients who can benefit from HDT. In this study, parameters associated with CR after HDT in 59 patients with newly diagnosed MM, sensitive to initial treatment and who received early intensification with autotransplantation are investigated.
Patients and methods

Patients
From June 1992 to August 2001, 59 patients (37 males, 22 females) with a median age of 54 years (range 38-69) with newly diagnosed MM, sensitive to the initial chemotherapy, underwent high-dose intensification followed by autologous stem cell transplant (HDT/SCT) at our institution. Diagnosis of MM was made according to the criteria of the Chronic Leukemia-Myeloma Task Force.
14 All patients had symptomatic disease. The initial characteristics of the patients are shown in Table 1 .
Initial treatment
The initial chemotherapy consisted of MP 15 in six cases, alternating courses of combination chemotherapy VCMP/ VBAP or BVMCP/VBAD 16 in 42 cases and VAD 17 or VBAD in 11 patients. The median time between initial treatment and HDT/SCT intensification was 8.5 months (range 5-20).
High-dose therapy
The source of stem cell was peripheral blood in 55 cases, bone marrow in three cases and bone marrow plus peripheral blood in one case. The harvest of peripheral blood stem cell was performed after mobilization by G-CSF 12 mg/kg/12 h/sc for 5 days (29 patients), G-CSF 12 mg/ kg/24 h/sc for 5 days (10 patients) or cyclophosphamide 1.5-3 g/m 2 and G-CSF (11 patients). The median of CD34 þ infused was 2.9 Â 10 6 /kg (range 1.4-14.5). The intensification regimen consisted of melphalan 140 mg/m 2 plus fractionated TBI 12 Gy in 21 patients, melphalan 200 mg/m 2 in 23 cases or busulfan-based regimens in 15 patients (busulfan plus cyclophosphamide in one case and busulfan plus melphalan in 14 patients). G-CSF at a dose of 5 mg/kg/day was administered in all patients from day þ 7 until granulocyte recovery.
Criteria of response
The criteria of response were those defined by the EMBT, ABMTR and IBMTR. 18 A complete remission (CR) required serum and urine negative immunofixation maintained for a minimum of 6 weeks, as well as less than 5% of bone marrow plasma cells. A partial response (PR) was defined as reduction of 50% or more of the serum M component and reduction of at least 90% in 24 h urine light chain excretion (or less than 200 mg) maintained for a minimum of 6 weeks. Minimal response was considered in those cases with either a reduction of 25-49% of the serum monoclonal protein or 50-89% in the urine light chain excretion.
Responses after autologous transplant were evaluated at 6 months from the procedure. Most patients received maintenance treatment with IFN with or without glucocorticoids. Relapse from CR required the reappearance of the original serum or urinary paraprotein, or X5% of bone marrow plasma cells, or the development of new lytic bone lesions, or plasmacytomas, or hypercalcemia.
Statistical analysis
The w 2 test was used, or the Fisher's exact test when required, for multiple comparisons. OS was calculated from the start of the initial treatment to the date of death or last visit. No patient died from transplant related-toxicity or in response. The Kaplan-Meier method was used to plot survival and progression-free survival curves and statistically compared by means of the log-rank test. 19 
Results
Complete remission
After initial chemotherapy the response rates were: CR 8%, PR 70% and MR 22%. Complete remission after HDT was achieved in 22 of the 59 patients. Thus, the CR rate was increased from 8 to 37% with treatment intensification.
Survival and event-free survival
The median EFS and OS from the initial treatment were 41 and 68 months, respectively (Figure 1 ). Concerning the subgroup of patients who achieved a CR after transplant, they had both a significantly longer EFS (median 47 vs 36 months; P ¼ 0.023) and OS (median not reached vs 60 months; P ¼ 0.006) than those who attained a lower degree of response (Figure 2) .
Predictors of response
The following pretransplant variables were analyzed in order to identify those that could predict CR achievement The pretransplant factors significantly associated to CR were a low M-protein size (ie serum p10 g/l and urine o0.5 g/24 h, Po0.0003) and a percentage of bone marrow plasma cells p5% (P ¼ 0.02) ( Table 2 ). Besides the tumor burden at the time of transplant, a trend toward a lower CR rate in those patients with a hemoglobin level o110 g/l (P ¼ 0.055) was also found. On logistic regression analysis, only the M-protein size retained its statistical significance (P ¼ 0.008).
Discussion
Autologous transplant is currently offered as part of frontline therapy to most patients with newly diagnosed MM. There is general agreement in that HDT/SCT increases the CR rate when compared to standard chemotherapy. However, there are only two randomized trials supporting the superiority of HDT/SCT in terms of EFS and OS. 3, 4 On the other hand, in one case control and two populationbased control studies, HDT was superior to conventional chemotherapy. [5] [6] [7] [8] [9] Nevertheless, a major concern in case control studies is the possibility of a selection bias. In fact, three studies have shown that patients with sensitive disease who were eligible for HDT/SCT, but who did not receive such treatment, had a survival similar to that of those who were intensified with HDT/SCT. 10, 11, 13 In addition, in two prospective randomized trials, HDT was not found to be superior to conventional chemotherapy. 8, 9 Currently, there are two large prospective trials (US Intergroup and PETHEMA) comparing HDT vs standard chemotherapy with not yet fully published results.
Even when the results of the autotransplant are better than those of standard chemotherapy, whether HDT is of benefit for the majority of patients or the impact on the overall benefit is only from certain subsets of patients is not clear. Concerning this point, there is increasing evidence that CR achievement is crucial for long-lasting response and prolonged survival after HDT/SCT. 12, 13, 20 Thus, in two single institution studies, 12, 13 patients with responding disease to the initial chemotherapy and who were in CR after receiving HDT intensification had an EFS and OS significantly longer than those who remained in PR. In fact, the latter group had similar EFS and OS than comparable patients who met the eligibility criteria for HDT but who did not receive HDT and were continued on standard chemotherapy. 12, 13 In consequence, it is likely that almost all the benefit from HDT is derived from the patients attaining CR post transplant. Interestingly, a small group of patients from the Alexanian series 12 who achieved CR with conventional therapy and who did not receive HDT intensification had the same EFS and OS as patients attaining CR after transplantation. This would indicate that the achievement of CR is the key factor for a favorable long-term outcome, regardless of the dose intensity required. However, whether or not patients achieving CR with conventional chemotherapy benefit from HDT intensification has not yet been established.
The identification of factors that can predict the CR attainment might be important to limit HDT/SCT to those patients most likely to benefit from the procedure. In our series, the CR increased from 8% with chemotherapy to 37% after HDT/SCT. As in the series by Alexanian et al, 12 patients who achieved CR had a significantly longer EFS and OS than those who attained a lower degree of response.
In the analysis of the pretransplant features associated to CR, the critical predictor of CR was the tumor burden at the time of transplant as measured by the M-protein size (serum p10 g/l and urine o0.5 g/24 h) and a percentage of bone marrow plasma cells of 5% or less. These results support those published by Alexanian et al most important feature to predict a CR after autologous transplantation. It is also of interest that the initial chemotherapy regimen does not seem to influence the results after HDT/SCT. Thus, while Alexanian et al 12 used continuous infusion chemotherapy with VAD, most of our patients received alkylating-based regimens with or without high-dose dexamethasone. The final CR rate after transplant was 37% in both studies.
This report stresses the importance of attaining a CR for a long-lasting disease control in patients with MM with chemosensitive disease to the initial chemotherapy undergoing HDT autotransplantation/intensification and identifies the pretransplant tumor burden as the crucial feature associated to complete remission. These results might be important to limit HDT/SCT to the patients most likely to benefit from the procedure. In fact, in patients with a pretransplant serum M-protein size higher than 20 g/l, the expected CR after HDT is lower than 10%. A different set of rules may apply when patients unresponsive to primary therapy are considered. 10, 21 
